CN103570674A - Preparation method of imatinib mesylate alpha crystal form - Google Patents

Preparation method of imatinib mesylate alpha crystal form Download PDF

Info

Publication number
CN103570674A
CN103570674A CN201210276326.8A CN201210276326A CN103570674A CN 103570674 A CN103570674 A CN 103570674A CN 201210276326 A CN201210276326 A CN 201210276326A CN 103570674 A CN103570674 A CN 103570674A
Authority
CN
China
Prior art keywords
sec
butyl alcohol
crystal form
imatinib mesylate
imatinib
Prior art date
Application number
CN201210276326.8A
Other languages
Chinese (zh)
Inventor
陈士明
潘志福
杨农纲
刘镇国
郭成寅
Original Assignee
浙江九洲药业股份有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 浙江九洲药业股份有限公司 filed Critical 浙江九洲药业股份有限公司
Priority to CN201210276326.8A priority Critical patent/CN103570674A/en
Publication of CN103570674A publication Critical patent/CN103570674A/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond

Abstract

The invention relates to the field of drug synthesis and discloses a preparation method of an imatinib mesylate alpha crystal form. In the preparation method, imatinib alkali is mixed with sec-butyl alcohol, and the mixture reacts with the methanesulfonic acid-sec-butyl alcohol mixed liquid to obtain the imatinib mesylate alpha crystal form. The preparation method disclosed by the invention realizes high yield and stable process and is suitable for industrial production of the imatinib mesylate alpha crystal form.

Description

A kind of preparation method of imatinib mesylate alfa crystal form

Technical field

The present invention relates to the synthetic field of medicine, relate to specifically a kind of preparation method of imatinib mesylate alfa crystal form.

Background technology

Imatinib mesylate, English name: Imatinib Mesilate, chemical name: 4-[(4-methyl isophthalic acid-piperazine) methyl]-N-[4-methyl-3-[[4-(3-pyridine)-2-pyrimidine] amino] phenyl]-aniline mesylate, molecular formula is C 29h 31n 7oCH 4sO 3, molecular weight is 589.71, structural formula is as follows:

A signal transduction inhibitor of company of Ta Shi Switzerland Novartis (Novartis) research and development, in 10 U.S. Initial Public Offering in May calendar year 2001, the Yi U.S., European Union, Japan and China are in more than 60 interior country's listings at present.

Research is found, imatinib mesylate all can suppress Bcr-Abl Tyrosylprotein kinase in vivo and in vitro on cell levels, can selectivity suppress Bcr-Abl positive cell line cell and the chronic myelocytic leukemia of Ph chromatin-positive, the propagation of acute lymphoblastic leukemia patient's new fresh cell and induce its apoptosis.In addition, it also can suppress platelet derived growth factor (PDGF) acceptor, STEM CELL FACTOR (SCF), the Tyrosylprotein kinase of c-Kit acceptor, thus suppress the cell behavior by PDGF and STEM CELL FACTOR mediation.Imatinib mesylate belongs to small molecules targeting anti-tumor medicine, is applicable to chronic phase patient after chronic myelocytic leukemia (CML) acute transformation phase, acceleration period or alpha-interferon therapy failure and can not excision or malignant gastrointestinal mesenchymal neoplasm (GIST) patient that shifts occurs.

US Patent No. 5521184 has been described imatinib and salt form thereof the earliest.International Patent Application WO 99/03854, WO2005/077933, WO2004/106326, WO2006/054314 and WO2007/023182 disclose imatinib mesylate α, β, α 2, H1, I, II, δ, ε crystal formation.

WO99/03854 discloses the preparation method of imatinib mesylate alfa crystal form and beta crystal.Wherein, alpha-crystal form is made solvent with ethanol, is mixed into suspension with imatinib alkali, adds methylsulfonic acid, after through a series of post-processing operation, prepare.But the alpha-crystal form that the method prepares is unstable, under state of nature, easily moisture absorption and be unformed, is unsuitable for medicinal application.

WO2005095379 discloses in the mixing solutions of alkyl alcohols or alkyl alcohol and alkyl acid esters and has prepared imatinib mesylate alfa crystal form, uses like this mixing solutions of alkyl alcohol and alkyl acid esters to be unfavorable for generating alpha-crystal form, causes on the contrary generating mixed crystal.

WO2011099039 discloses take imatinib alkali as raw material, and the trimethyl carbinol is the method that solvent is prepared imatinib mesylate alfa crystal form.Be specially: imatinib alkali is dissolved into suspension with the trimethyl carbinol, and at 30~60 ℃ of mixing solutionss that drip methylsulfonic acids and the trimethyl carbinol, heated mixt is to refluxing cooling, filtration, crystallization, dry.In this preparation method, require the purity of imatinib alkali to be greater than 99%, the moisture content of solvent is greatly about 0.01 to 0.015, and dripping methylsulfonic acid and trimethyl carbinol mixing solutions time is 1~4 hour, and alkali is 2~10 times of methylsulfonic acid quality.The method is high to the purity requirement of raw material, also needs to control solvent water content, and complicated operation, is unsuitable for suitability for industrialized production.

In view of the series of problems existing in prior art, be necessary the preparation method of imatinib mesylate alfa crystal form to be further improved, development yield is high, process stabilizing, be applicable to the preparation method of the imatinib mesylate alfa crystal form of suitability for industrialized production.

Summary of the invention

The preparation method who the invention provides a kind of imatinib mesylate alfa crystal form, the method is simple to operate, and yield is high, is suitable for suitability for industrialized production.

The technical solution used in the present invention is:

After imatinib alkali mixes with sec-butyl alcohol, react with the mixing solutions of methylsulfonic acid and sec-butyl alcohol, make imatinib mesylate alfa crystal form.

After imatinib alkali mixes with sec-butyl alcohol, along with the dosage of sec-butyl alcohol increases, imatinib alkali can become and is dissolved in sec-butyl alcohol completely from being not exclusively dissolved in sec-butyl alcohol.Through contriver's experiment, when the mass ratio of sec-butyl alcohol and imatinib alkali is greater than 20 times, imatinib can be dissolved in sec-butyl alcohol completely; When the mass ratio of sec-butyl alcohol and imatinib alkali is 8~20:1, imatinib mesylate can form suspendible shape in sec-butyl alcohol, is more conducive to separate out imatinib mesylate alfa crystal form.

As preferably, imatinib alkali mixes with sec-butyl alcohol, and the mass ratio of sec-butyl alcohol and imatinib alkali is 8~20:1.

As preferably, in the mixing solutions of methylsulfonic acid and sec-butyl alcohol, the mass ratio of sec-butyl alcohol and methylsulfonic acid is 15:1.

As preferably, after sec-butyl alcohol mixes with imatinib alkali, be heated to 60~102 ℃.

Through contriver's experiment, after sec-butyl alcohol mixes with imatinib alkali, the temperature of heating is higher, and the solubleness of imatinib alkali is higher, reacts faster with the mixing solutions of methylsulfonic acid and sec-butyl alcohol, and the imatinib mesylate alfa crystal form color of generation is pure.

Preferred, sec-butyl alcohol is heated to reflux temperature after mixing with imatinib alkali.

One embodiment of the present invention are: imatinib alkali is heated to reflux temperature after mixing with sec-butyl alcohol, react with the mixing solutions of methylsulfonic acid and sec-butyl alcohol, after simple aftertreatment, obtain imatinib mesylate alfa crystal form.

Simple aftertreatment of the present invention is for filtering the imatinib mesylate alfa crystal form making, wash, being dried.

Filtration is preferably and is cooled to 25 ℃, and drying nitrogen protection is lower filters, and due to the stable chemical nature of nitrogen, is difficult for reacting with other materials, is commonly used for protection gas, and dry nitrogen does not have moisture, makes crystal formation more stable.

Washing is preferably sec-butyl alcohol drip washing.

Be dried and be preferably vacuum-drying at 65 ℃.

The invention provides a kind of method of imatinib mesylate alfa crystal form of preparing as solvent with sec-butyl alcohol, the method has utilized imatinib alkali can be dissolved in sec-butyl alcohol, and imatinib mesylate is not soluble in the character of sec-butyl alcohol, prepared imatinib mesylate alfa crystal form yield is high, crystal formation is pure, and simple to operate, be applicable to suitability for industrialized production.

Accompanying drawing explanation

Fig. 1 shows the imatinib mesylate alfa crystal form x-ray diffractogram of powder spectrum of the embodiment of the present invention 1 preparation.

Fig. 2 shows the imatinib mesylate alfa crystal form DSC collection of illustrative plates of the embodiment of the present invention 1 preparation.

Embodiment

In order further to understand the present invention, below in conjunction with embodiment, the preparation method of a kind of imatinib mesylate alfa crystal form provided by the invention is elaborated.It will be appreciated that, it is just further description feature of the present invention that these embodiment describe, rather than the restriction to the scope of the invention or the claims in the present invention scope.

Embodiment 1:

In the four-hole reaction flask of 500ml, drop into 25g imatinib alkali and 200g sec-butyl alcohol, be heated to 102 ℃, insulation.To splashing into the mixing solutions of methylsulfonic acid (4.875g) with sec-butyl alcohol (75g) in reaction flask; dropwise; insulation 0.5h; naturally cool to 25 ℃; suction filtration under nitrogen protection, with the drip washing of 25ml sec-butyl alcohol, drains in the vacuum drying oven that is placed on 65 ℃ and dries 12h; obtain imatinib mesylate alfa crystal form 28.37g, yield 95.0%.Utilize powder x-ray diffraction method and dsc (DSC) to measure the imatinib mesylate alfa crystal form of preparation.Fig. 1 is shown in by XRPD collection of illustrative plates, and reflection angle 2 θ are: 4.940,10.495,11.285,11.916,12.227,12.935,13.885,14.946,16.506,17.746,18.118,18.651,19.105,19.864,21.310,21.566,22.688,23.181,23.769,25.011,26.372,27.395,28.064,28.536,28.871,30.033,30.412,32.060,32.635.Fig. 2 is shown in by DSC collection of illustrative plates, and peak value is 229.4 ℃.

Embodiment 2:

In the four-hole reaction flask of 500ml, drop into 25g imatinib alkali and 300g sec-butyl alcohol, be heated to 102 ℃, insulation.To splashing into the mixing solutions of methylsulfonic acid (4.875g) with sec-butyl alcohol (75g) in reaction flask; dropwise; insulation 0.5h; naturally cool to 25 ℃; suction filtration under nitrogen protection, with the drip washing of 25ml sec-butyl alcohol, drains in the vacuum drying oven that is placed on 65 ℃ and dries 12h; obtain imatinib mesylate alfa crystal form 28.26g, yield 94.6%.Utilize differential heat scanning method (DSC) to measure the imatinib mesylate alfa crystal form of preparation.Dsc figure spectrum peak is 226.5 ℃.

Embodiment 3:

In the four-hole reaction flask of 1000ml, drop into 25g imatinib alkali and 500g sec-butyl alcohol, be heated to 102 ℃, insulation.To splashing into the mixing solutions of methylsulfonic acid (4.875g) with sec-butyl alcohol (75g) in reaction flask; dropwise; insulation 0.5h; naturally cool to 25 ℃; suction filtration under nitrogen protection, with the drip washing of 25ml sec-butyl alcohol, drains in the vacuum drying oven that is placed on 65 ℃ and dries 12h; obtain imatinib mesylate alfa crystal form 28.24g, yield 94.5%.Utilize differential heat scanning method (DSC) to measure the imatinib mesylate alfa crystal form of preparation.Dsc figure spectrum peak is 227.2 ℃.

Embodiment 4:

In the four-hole reaction flask of 500ml, drop into 25g imatinib alkali and 200g sec-butyl alcohol, be heated to 60 ℃, insulation.To splashing into the mixing solutions of methylsulfonic acid (4.875g) with sec-butyl alcohol (75g) in reaction flask; dropwise; insulation 0.5h; naturally cool to 25 ℃; suction filtration under nitrogen protection, with the drip washing of 25ml sec-butyl alcohol, drains in the vacuum drying oven that is placed on 65 ℃ and dries 12h; obtain imatinib mesylate alfa crystal form 28.27g, yield 94.6%.Utilize differential heat scanning method (DSC) to measure the imatinib mesylate alfa crystal form of preparation.Dsc figure spectrum peak is 227.2 ℃.

Embodiment 5:

In the four-hole reaction flask of 500ml, drop into 25g imatinib alkali and 200g sec-butyl alcohol, be heated to 80 ℃, insulation.To splashing into the mixing solutions of methylsulfonic acid (4.875g) with sec-butyl alcohol (75g) in reaction flask; dropwise; insulation 0.5h; naturally cool to 25 ℃; suction filtration under nitrogen protection, with the drip washing of 25ml sec-butyl alcohol, drains in the vacuum drying oven that is placed on 65 ℃ and dries 12h; obtain imatinib mesylate alfa crystal form 28.31g, yield 94.8%.Utilize differential heat scanning method (DSC) to measure the imatinib mesylate alfa crystal form of preparation.Dsc figure spectrum peak is 226.5 ℃.

Embodiment 6:

In the four-hole reaction flask of 1000ml, drop into 25g imatinib alkali and 500g sec-butyl alcohol, be heated to 100 ℃, insulation.To splashing into the mixing solutions of methylsulfonic acid (4.875g) with sec-butyl alcohol (75g) in reaction flask; dropwise; insulation 0.5h; naturally cool to 25 ℃; suction filtration under nitrogen protection, with the drip washing of 25ml sec-butyl alcohol, drains in the vacuum drying oven that is placed on 65 ℃ and dries 12h; obtain imatinib mesylate alfa crystal form 28.28g, yield 94.7%.Utilize differential heat scanning method (DSC) to measure the imatinib mesylate alfa crystal form of preparation.Dsc figure spectrum peak is 226.1 ℃.

The explanation of above embodiment is just for helping to understand method of the present invention and core concept thereof.It should be pointed out that for those skilled in the art, under the premise without departing from the principles of the invention, can also carry out some improvement and modification to the present invention, these improvement and modification also fall in the protection domain of the claims in the present invention.

Claims (5)

1. a preparation method for imatinib mesylate alfa crystal form, is characterized in that, after imatinib alkali is mixed with sec-butyl alcohol, reacts with the mixing solutions of methylsulfonic acid and sec-butyl alcohol, prepares imatinib mesylate alfa crystal form.
2. preparation method according to claim 1, is characterized in that, comprises following two steps:
A) drop into imatinib alkali and sec-butyl alcohol, heating;
B) react with the mixing solutions of methylsulfonic acid and sec-butyl alcohol.
3. preparation method according to claim 2, is characterized in that, in described step a, the mass ratio of sec-butyl alcohol and imatinib alkali is 8~20:1.
4. preparation method according to claim 2, is characterized in that, in the mixed solution of described step b methylsulfonic acid sec-butyl alcohol, the mass ratio of sec-butyl alcohol and methylsulfonic acid is 15:1.
5. preparation method according to claim 2, is characterized in that, described temperature need be heated to 60 ℃~102 ℃.
CN201210276326.8A 2012-08-04 2012-08-04 Preparation method of imatinib mesylate alpha crystal form CN103570674A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201210276326.8A CN103570674A (en) 2012-08-04 2012-08-04 Preparation method of imatinib mesylate alpha crystal form

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN201210276326.8A CN103570674A (en) 2012-08-04 2012-08-04 Preparation method of imatinib mesylate alpha crystal form

Publications (1)

Publication Number Publication Date
CN103570674A true CN103570674A (en) 2014-02-12

Family

ID=50043459

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201210276326.8A CN103570674A (en) 2012-08-04 2012-08-04 Preparation method of imatinib mesylate alpha crystal form

Country Status (1)

Country Link
CN (1) CN103570674A (en)

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005095379A2 (en) * 2004-04-02 2005-10-13 Instytut Farmaceutyczny Crystalline methanesulfonic acid addition salts of imatinib
WO2006024863A1 (en) * 2004-09-02 2006-03-09 Cipla Limited Stable crystal form of imatinib mesylate and process for the preparation thereof
WO2011099039A1 (en) * 2010-02-15 2011-08-18 Reliance Life Sciences Pvt. Ltd. Process for the preparation of alpha form of imatinib mesylate
CN102321070A (en) * 2011-07-27 2012-01-18 江苏先声药物研究有限公司 Method for preparing imatinib methylolsulfonate alpha crystal through inverse solvent recrystallization method

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005095379A2 (en) * 2004-04-02 2005-10-13 Instytut Farmaceutyczny Crystalline methanesulfonic acid addition salts of imatinib
WO2006024863A1 (en) * 2004-09-02 2006-03-09 Cipla Limited Stable crystal form of imatinib mesylate and process for the preparation thereof
WO2011099039A1 (en) * 2010-02-15 2011-08-18 Reliance Life Sciences Pvt. Ltd. Process for the preparation of alpha form of imatinib mesylate
CN102321070A (en) * 2011-07-27 2012-01-18 江苏先声药物研究有限公司 Method for preparing imatinib methylolsulfonate alpha crystal through inverse solvent recrystallization method

Similar Documents

Publication Publication Date Title
US9334263B2 (en) Compositions useful for treating disorders related to kit
CN105189515B (en) Furopyridine class as bromine structural domain inhibitor
EP3057969B1 (en) Compositions useful for treating disorders related to kit
JP6322205B2 (en) Pyrimidine-2,4-diamine derivatives for cancer treatment
AU2014256635B2 (en) Deuterated diaminopyrimidine compounds and pharmaceutical compositions comprising such compounds
CN105934432B (en) The diamine derivative of 2,4 disubstituted benzenes 1,5 and its application and pharmaceutical composition prepared therefrom and Pharmaceutical composition
EP2651918B1 (en) Crystalline forms of 5-chloro-n2-(2-isopropoxy-5-methyl-4-piperidin-4-yl-phenyl)-n4[2-(propane-2-sulfonyl)-phenyl]-pyrimidine-2,4-diamine
ES2634291T3 (en) Salts of 4-methyl-N- [3- (4-methyl-imidazol-1-yl) -5-trifluoromethyl-phenyl] -3- (4-pyridin-3-yl-pyrimidin-2-ylamino) -benzamide
EP3094329B1 (en) Bicyclic heterocyclyl derivatives as irak4 inhibitors
EP1389617B1 (en) Heterocyclic compound and antitumor agent containing the same as active ingredient
WO2016007727A1 (en) Triazolopyridines and triazolopyrazines as lsd1 inhibitors
EP3013813B1 (en) Heteroaromatic compounds and their use as dopamine d1 ligands
JP5894153B2 (en) Nilotinib salts and their crystalline forms
AU2011254550B2 (en) Novel pyrimidine derivatives
CN101580477B (en) Dehydroabietylamine derivatives and application thereof in bactericidal and antineoplastic medicaments
CA2545527C (en) Pyrazole derivatives as inhibitors of receptor tyrosyne kinases
JP4938311B2 (en) 1- (2H) -Isoquinolone derivatives
CN104302626A (en) 4,4-disubstituted-1,4-dihydropyrimidines and the use thereof as medicaments for the treatment of hepatitis b
KR100820543B1 (en) 2-Amino-3-Alkyl-Pyrimidone Derivatives as GSK3.Beta. Inhibitors
KR20130085444A (en) Crystalline forms of 4-methyl-n-[3-(4-methyl-imidazol-1-yl)-5-trifluoromethyl-phenyl]-3-(4-pyridin-3-yl-pyrimidin-2-ylamino)-benzamide
ES2375735T3 (en) Useful pirazolilaminopiridine derivatives as quinase inhibitors.
CN101759683B (en) Preparation method of hydrindene amide compound, medical composition comprising hydrindene amide compound and application thereof as protein kinase inhibitor
CN106536506A (en) Benzimidazole derivatives as erbb tyrosine kinase inhibitors for the treatment of cancer
KR100956052B1 (en) 3-substituted-4-pyrimidone derivatives
CA2917735C (en) Protein tyrosine kinase modulators and methods of use

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
EXSB Decision made by sipo to initiate substantive examination
SE01 Entry into force of request for substantive examination
RJ01 Rejection of invention patent application after publication
RJ01 Rejection of invention patent application after publication

Application publication date: 20140212